Q3 2024 · 13F-HR
Fairmount Funds Management LLCholdings as filed
Filed 2024-11-14 · accession 0001104659-24-118833
$1.23B
Reported value
15
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $212.1M | 17.2% | 2,360,077 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $172.6M | 14.0% | 1,687,064 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $120.3M | 9.76% | 2,048,647 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $118.2M | 9.58% | 4,018,101 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $81.8M | 6.63% | 3,202,798 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $80.1M | 6.49% | 3,204,841 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $78.7M | 6.38% | 3,211,922 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $78.4M | 6.36% | 3,445,813 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $73.9M | 6.00% | 2,700,691 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $67.2M | 5.45% | 6,225,641 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS INC | $43.2M | 3.51% | 3,103,448 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $39.1M | 3.17% | 3,554,129 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $32.7M | 2.65% | 1,284,169 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $32.0M | 2.60% | 1,892,806 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $2.8M | 0.23% | 123,538 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.